Laura Kenny Selected Research

Breast Neoplasms (Breast Cancer)

4/2024	Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study.
4/2024	Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.
1/2023	Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
1/2023	Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management.
11/2022	Eribulin for the treatment of advanced breast cancer: A prospective observational registry study.
7/2021	Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.
1/2019	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
12/2018	Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer.
1/2018	Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
9/2017	IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura Kenny Research Topics

Disease

14	Breast Neoplasms (Breast Cancer) 04/2024 - 09/2007
11	Neoplasms (Cancer) 04/2024 - 06/2012
4	Neoplasm Metastasis (Metastasis) 01/2014 - 09/2007
1	Cognitive Dysfunction 01/2023
1	Triple Negative Breast Neoplasms 01/2023
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2022
1	Pressure Ulcer (Bedsore) 01/2021
1	Neuralgia (Stump Neuralgia) 01/2019
1	Chronic Pain 01/2019
1	Pain (Aches) 01/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2019
1	Necrosis 12/2018
1	Lung Neoplasms (Lung Cancer) 12/2018
1	Renal Cell Carcinoma (Grawitz Tumor) 02/2016
1	Chromosomal Instability (Chromosome Stability) 01/2014

Drug/Important Bio-Agent (IBA)

3	Aromatase InhibitorsIBA 04/2024 - 09/2017
3	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 01/2014
3	Glyphosate (Roundup)IBA 01/2019 - 01/2018
2	Circulating Tumor DNAIBA 04/2024 - 01/2019
2	Steryl-Sulfatase (Steroid Sulfatase)IBA 01/2018 - 09/2017
2	irosustatIBA 01/2018 - 09/2017
2	ThymidineIBA 02/2016 - 06/2012
1	Biomarkers (Surrogate Marker)IBA 04/2024
1	Cell-Free Nucleic AcidsIBA 04/2024
1	AntigensIBA 04/2024
1	Fulvestrant (Faslodex)FDA Link 01/2023
1	RNA Polymerase II (RNA Polymerase B)IBA 01/2023
1	eribulin FDA Link 11/2022
1	Estrogen ReceptorsIBA 07/2021
1	Capsaicin (Zostrix)FDA Link 01/2019
1	Caspase 3 (Caspase-3)IBA 12/2018
1	HerbicidesIBA 01/2018
1	Angiogenesis InhibitorsIBA 02/2016
1	Indicators and Reagents (Reagents)IBA 01/2014
1	CyclinsIBA 01/2014
1	NucleotidesIBA 01/2014
1	LigandsIBA 12/2011
1	IntegrinsIBA 12/2011
1	antibiotic K 4 (K 4)IBA 12/2011
1	AH 111585IBA 12/2011
1	Epirubicin (Ellence)FDA LinkGeneric 09/2007
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2007
1	Fluorouracil (Carac)FDA LinkGeneric 09/2007
1	alovudineIBA 09/2007

Therapy/Procedure

7	Therapeutics 04/2024 - 06/2012
6	Drug Therapy (Chemotherapy) 04/2024 - 09/2007
2	Extracorporeal Membrane Oxygenation 01/2022 - 01/2021
1	Adjuvant Chemotherapy 04/2024
1	Aftercare (After-Treatment) 09/2007